Pune, India, February 2020, MRFR Press Release/- Market Research Future has published a Half-Cooked Research Report on the Global Cardiac Mapping Market.
According to MRFR analysis, Global Cardiac Mapping Market is expected to register a CAGR of 8.4% during the forecast period of 2019 to 2025 and was valued at USD 1.3 Billion in 2018.
The normal heart has a ‘built-in’ electrical system that controls cardiac rhythm and pulse rate. This allows the heart chambers to beat in a coordinated fashion. Cardiac arrhythmias such as bradycardia, atrial flutter, and tachycardia can develop due to a sedentary lifestyle, lack of exercise, and other congenital problems.
According to the Centers for Disease Control and Prevention (CDC), the prevalence of atrial fibrillation in the US ranged from 2.7 to 6.1 million, which is expected to increase with the ageing population. Catheter guided mapping is a minimally invasive procedure that aims to monitor the irregular heartbeats by navigating to abnormal tissue responsible for causing the arrhythmia.
The global cardiac mapping market is currently dominated by several market players. The key players are involved in expansion, acquisition, and strategic collaborations to maintain their global footprint. For instance, in February 2020, Rhythm AI agreed to a research collaboration with Biosense Webster Inc. The agreement grants the company access to certain data from the Biosense Webster’s CARTO3 System to support a multi-center clinical trial of its STAR Mapping system.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to hold the largest market share owing to the higher adoption rates of cardiac mapping, available healthcare infrastructure, and the presence of prominent players in this region. The cardiac mapping market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European cardiac mapping market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac mapping market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising prevalence of cardiovascular diseases and the expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing. The cardiac mapping market in the Middle East & Africa has been divided into the Middle East and Africa.
The Global Cardiac Mapping Market has been segmented based on product, indication, and end user.
The market, based on product, has been divided into contact with cardiac mapping systems and non- contact cardiac mapping systems. The contact cardiac mapping systems are likely to hold maximum market share in the global cardiac mapping market owing to its ease of access across the globe.
The cardiac mapping market based on indication has been segregated into atrial fibrillation,
atrial flutter, atrioventricular nodal reentrant tachycardia (AVNRT), Wolff-Parkinson-White Syndrome (WPW), and others. The atrial fibrillation segment is anticipated to hold the largest share in the market due to a large number of patients suffering from the condition.
The end user segments of the cardiac mapping market are hospitals, clinics, diagnostic centers, and others. The hospitals segment is expected to hold the largest share of the market, as these are the primary locations where patients receive diagnosis & treatment.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/cardiac-mapping-market-8786
Some of the key players in the Global Cardiac Mapping Market are Abbott Laboratories, GE Healthcare, Boston Scientific Corporation, Medtronic plc., Johnson & Johnson, Koninklijke Philips N.V., Hill-Rom Services, Inc., and others.